[{"indications": "Indications\u00a0see notes above and under Dose", "name": "PENICILLAMINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Penicillamine"], "cautions": "Cautions\u00a0\n(From Penicillamine: British National Formulary)\nPenicillamine has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.Blood counts, including platelets, and urine examinations should be carried out before starting treatment and then every 1 or 2 weeks for the first 2 months then every 4 weeks to detect blood disorders and proteinuria (they should also be carried out in the week after any dose increase). A reduction in platelet count calls for discontinuation with subsequent re-introduction at a lower dosage and then, if possible, gradual increase. Proteinuria, associated with immune complex nephritis, occurs in up to 30% of patients, but may resolve despite continuation of treatment; treatment may be continued provided that renal function tests remain normal, oedema is absent, and the 24-hour urinary excretion of protein does not exceed 2\u00a0g.Nausea may occur but is not usually a problem provided that penicillamine is taken before food or on retiring and that low initial doses are used and only gradually increased. Loss of taste can occur about 6 weeks after treatment is started but usually returns 6 weeks later irrespective of whether treatment is discontinued; mineral supplements are not recommended. Rashes are a common side-effect. Those that occur in the first few months of treatment disappear when the drug is stopped and treatment may then be re-introduced at a lower dose level and gradually increased. Late rashes are more resistant and often necessitate discontinuation of treatment.Patients who are hypersensitive to penicillin may react rarely to penicillamine.; concomitant nephrotoxic\r\ndrugs (increased risk of toxicity); gold\r\ntreatment (avoid concomitant use if adverse reactions to gold); interactions: Appendix 1 (penicillamine)Blood counts and urine tests\u00a0See %s\n(From Penicillamine: British National Formulary)\nPenicillamine has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.Blood counts, including platelets, and urine examinations should be carried out before starting treatment and then every 1 or 2 weeks for the first 2 months then every 4 weeks to detect blood disorders and proteinuria (they should also be carried out in the week after any dose increase). A reduction in platelet count calls for discontinuation with subsequent re-introduction at a lower dosage and then, if possible, gradual increase. Proteinuria, associated with immune complex nephritis, occurs in up to 30% of patients, but may resolve despite continuation of treatment; treatment may be continued provided that renal function tests remain normal, oedema is absent, and the 24-hour urinary excretion of protein does not exceed 2\u00a0g.Nausea may occur but is not usually a problem provided that penicillamine is taken before food or on retiring and that low initial doses are used and only gradually increased. Loss of taste can occur about 6 weeks after treatment is started but usually returns 6 weeks later irrespective of whether treatment is discontinued; mineral supplements are not recommended. Rashes are a common side-effect. Those that occur in the first few months of treatment disappear when the drug is stopped and treatment may then be re-introduced at a lower dose level and gradually increased. Late rashes are more resistant and often necessitate discontinuation of treatment.Patients who are hypersensitive to penicillin may react rarely to penicillamine.. Longer intervals may be adequate\r\nin cystinuria and Wilson\u2019s disease. Consider withdrawal\r\nif platelet count falls below 120\u00a0000/mm3 or white blood\r\ncells below 2500/mm3 or if 3 successive falls within reference\r\nrange (can restart at reduced dose when counts return\r\nto within reference range but permanent withdrawal necessary\r\nif recurrence of leucopenia or thrombocytopenia)Counselling\u00a0Warn patient to\r\ntell doctor promptly if sore throat, fever, infection, non-specific\r\nillness, unexplained bleeding and bruising, purpura, mouth ulcers,\r\nor rashes develop", "side-effects": "Side-effects\u00a0(see also notes above) initially nausea, anorexia, fever,\r\nand skin reactions; taste loss (mineral supplements not recommended);\r\nblood disorders including thrombocytopenia, leucopenia, agranulocytosis\r\nand aplastic anaemia; proteinuria, rarely haematuria (withdraw immediately\r\nand seek specialist advice); haemolytic anaemia, pancreatitis, cholestatic\r\njaundice, nephrotic syndrome, lupus erythematosus-like syndrome, myasthenia\r\ngravis-like syndrome, neuropathy, polymyositis (rarely with cardiac\r\ninvolvement), dermatomyositis, mouth ulcers, stomatitis, alopecia,\r\nbronchiolitis and pneumonitis, pemphigus, Goodpasture\u2019s syndrome,\r\nand Stevens-Johnson syndrome also reported; male and female breast\r\nenlargement reported; in non-rheumatoid conditions rheumatoid arthritis-like\r\nsyndrome also reported; late rashes (consider withdrawing treatment)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5295.htm", "doses": ["Severe active rheumatoid arthritis, administered on expert\r\nadvice, adult over 18 years, initially\r\n125\u2013250\u00a0mg daily for 1 month increased by similar amounts at intervals\r\nof not less than 4 weeks to usual maintenance of 500\u2013750\u00a0mg daily\r\nin divided doses; max. 1.5\u00a0g daily; if remission sustained for 6 months,\r\nreduction of daily dose by 125\u2013250\u00a0mg every 12 weeks may be attempted; elderly initially up to 125\u00a0mg daily for 1 month\r\nincreased by similar amounts at intervals of not less than 4 weeks;\r\nmax. 1\u00a0g daily", "Wilson\u2019s disease, autoimmune hepatitis, and cystinuria, section 9.8.1"], "pregnancy": "Pregnancy\u00a0fetal abnormalities reported rarely; avoid if possible"}, {"indications": "Indications\u00a0see under Dose below", "name": "PENICILLAMINE - WILSON\u2019S DISEASE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.8 Metabolic disorders", "9.8.1 Drugs used in metabolic disorders", "Wilson\u2019s disease"], "cautions": "Cautions\u00a0section 10.1.3; also neurological involvement in Wilson\u2019s disease", "side-effects": "Side-effects\u00a0section 10.1.3; also\r\nneuropathy (especially if previous neurological involvement in Wilson\u2019s\r\ndisease\u2014prophylactic pyridoxine recommended, see section 9.6.2)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5177.htm", "doses": ["Wilson\u2019s disease, 1.5\u20132\u00a0g daily in divided doses before food; max.\r\n2\u00a0g daily for 1 year; maintenance 0.75\u20131\u00a0g daily; elderly 20\u00a0mg/kg daily in divided doses, adjusted according to response; child under 12 years see BNF for Children", "Autoimmune hepatitis (used rarely; after disease controlled\r\nwith corticosteroids), initially 500\u00a0mg daily in\r\ndivided doses increased slowly over 3 months; usual maintenance dose\r\n1.25\u00a0g daily; elderly not recommended", "Cystinuria, therapeutic, 1\u20133\u00a0g daily in divided doses before\r\nfood, adjusted to maintain urinary cystine below 200\u00a0mg/litre; prophylactic\r\n(maintain urinary cystine below 300\u00a0mg/litre) 0.5\u20131\u00a0g at bedtime;\r\nmaintain adequate fluid intake (at least 3\u00a0litres daily); child and elderly minimum\r\ndose to maintain urinary cystine below 200\u00a0mg/litre", "Severe active rheumatoid arthritis, section 10.1.3"], "pregnancy": "Pregnancy\u00a0section 10.1.3"}, {"indications": "Indications\u00a0see notes above and under Dose", "name": "PENICILLAMINE - PENICILLAMINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Penicillamine"], "cautions": "Cautions\u00a0\n(From Penicillamine: British National Formulary)\nPenicillamine has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.Blood counts, including platelets, and urine examinations should be carried out before starting treatment and then every 1 or 2 weeks for the first 2 months then every 4 weeks to detect blood disorders and proteinuria (they should also be carried out in the week after any dose increase). A reduction in platelet count calls for discontinuation with subsequent re-introduction at a lower dosage and then, if possible, gradual increase. Proteinuria, associated with immune complex nephritis, occurs in up to 30% of patients, but may resolve despite continuation of treatment; treatment may be continued provided that renal function tests remain normal, oedema is absent, and the 24-hour urinary excretion of protein does not exceed 2\u00a0g.Nausea may occur but is not usually a problem provided that penicillamine is taken before food or on retiring and that low initial doses are used and only gradually increased. Loss of taste can occur about 6 weeks after treatment is started but usually returns 6 weeks later irrespective of whether treatment is discontinued; mineral supplements are not recommended. Rashes are a common side-effect. Those that occur in the first few months of treatment disappear when the drug is stopped and treatment may then be re-introduced at a lower dose level and gradually increased. Late rashes are more resistant and often necessitate discontinuation of treatment.Patients who are hypersensitive to penicillin may react rarely to penicillamine.; concomitant nephrotoxic\r\ndrugs (increased risk of toxicity); gold\r\ntreatment (avoid concomitant use if adverse reactions to gold); interactions: Appendix 1 (penicillamine)Blood counts and urine tests\u00a0See %s\n(From Penicillamine: British National Formulary)\nPenicillamine has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.Blood counts, including platelets, and urine examinations should be carried out before starting treatment and then every 1 or 2 weeks for the first 2 months then every 4 weeks to detect blood disorders and proteinuria (they should also be carried out in the week after any dose increase). A reduction in platelet count calls for discontinuation with subsequent re-introduction at a lower dosage and then, if possible, gradual increase. Proteinuria, associated with immune complex nephritis, occurs in up to 30% of patients, but may resolve despite continuation of treatment; treatment may be continued provided that renal function tests remain normal, oedema is absent, and the 24-hour urinary excretion of protein does not exceed 2\u00a0g.Nausea may occur but is not usually a problem provided that penicillamine is taken before food or on retiring and that low initial doses are used and only gradually increased. Loss of taste can occur about 6 weeks after treatment is started but usually returns 6 weeks later irrespective of whether treatment is discontinued; mineral supplements are not recommended. Rashes are a common side-effect. Those that occur in the first few months of treatment disappear when the drug is stopped and treatment may then be re-introduced at a lower dose level and gradually increased. Late rashes are more resistant and often necessitate discontinuation of treatment.Patients who are hypersensitive to penicillin may react rarely to penicillamine.. Longer intervals may be adequate\r\nin cystinuria and Wilson\u2019s disease. Consider withdrawal\r\nif platelet count falls below 120\u00a0000/mm3 or white blood\r\ncells below 2500/mm3 or if 3 successive falls within reference\r\nrange (can restart at reduced dose when counts return\r\nto within reference range but permanent withdrawal necessary\r\nif recurrence of leucopenia or thrombocytopenia)Counselling\u00a0Warn patient to\r\ntell doctor promptly if sore throat, fever, infection, non-specific\r\nillness, unexplained bleeding and bruising, purpura, mouth ulcers,\r\nor rashes develop", "side-effects": "Side-effects\u00a0(see also notes above) initially nausea, anorexia, fever,\r\nand skin reactions; taste loss (mineral supplements not recommended);\r\nblood disorders including thrombocytopenia, leucopenia, agranulocytosis\r\nand aplastic anaemia; proteinuria, rarely haematuria (withdraw immediately\r\nand seek specialist advice); haemolytic anaemia, pancreatitis, cholestatic\r\njaundice, nephrotic syndrome, lupus erythematosus-like syndrome, myasthenia\r\ngravis-like syndrome, neuropathy, polymyositis (rarely with cardiac\r\ninvolvement), dermatomyositis, mouth ulcers, stomatitis, alopecia,\r\nbronchiolitis and pneumonitis, pemphigus, Goodpasture\u2019s syndrome,\r\nand Stevens-Johnson syndrome also reported; male and female breast\r\nenlargement reported; in non-rheumatoid conditions rheumatoid arthritis-like\r\nsyndrome also reported; late rashes (consider withdrawing treatment)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/5295.htm", "doses": ["Severe active rheumatoid arthritis, administered on expert\r\nadvice, adult over 18 years, initially\r\n125\u2013250\u00a0mg daily for 1 month increased by similar amounts at intervals\r\nof not less than 4 weeks to usual maintenance of 500\u2013750\u00a0mg daily\r\nin divided doses; max. 1.5\u00a0g daily; if remission sustained for 6 months,\r\nreduction of daily dose by 125\u2013250\u00a0mg every 12 weeks may be attempted; elderly initially up to 125\u00a0mg daily for 1 month\r\nincreased by similar amounts at intervals of not less than 4 weeks;\r\nmax. 1\u00a0g daily", "Wilson\u2019s disease, autoimmune hepatitis, and cystinuria, section 9.8.1"], "pregnancy": "Pregnancy\u00a0fetal abnormalities reported rarely; avoid if possible"}]